Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(7):852–854. doi: 10.1038/bjc.1997.474

Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy.

K T Kelsey 1, D Ross 1, R D Traver 1, D C Christiani 1, Z F Zuo 1, M R Spitz 1, M Wang 1, X Xu 1, B K Lee 1, B S Schwartz 1, J K Wiencke 1
PMCID: PMC2228056  PMID: 9328142

Abstract

The NAD(P)H quinone oxidoreductase (NQO1:EC 1.6.99.2) is an important biotransformation enzyme system that is also known to metabolize important novel chemotherapeutic compounds. The gene that codes for this enzyme has recently been found to be polymorphic in humans. Here, we describe the ethnic distribution of the polymorphism and note that this may have implications for anti-tumour drug development and use.

Full text

PDF
852

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berenberg J. L. Response to treatment of breast cancer. Breast Cancer Res Treat. 1991 May;18 (Suppl 1):S147–S155. doi: 10.1007/BF02633548. [DOI] [PubMed] [Google Scholar]
  2. Elledge R. M., Clark G. M., Chamness G. C., Osborne C. K. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994 May 4;86(9):705–712. doi: 10.1093/jnci/86.9.705. [DOI] [PubMed] [Google Scholar]
  3. Fitzsimmons S. A., Workman P., Grever M., Paull K., Camalier R., Lewis A. D. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst. 1996 Mar 6;88(5):259–269. doi: 10.1093/jnci/88.5.259. [DOI] [PubMed] [Google Scholar]
  4. Modiano M. R., Villar-Werstler P., Meister J., Figueroa-Vallés N. Cancer in Hispanics: issues of concern. J Natl Cancer Inst Monogr. 1995;(18):35–39. [PubMed] [Google Scholar]
  5. Philpott N. J., Bevan D. H., Gordon-Smith E. C. Secondary leukaemia after MMM combined modality therapy for breast carcinoma. Lancet. 1993 May 15;341(8855):1289–1289. doi: 10.1016/0140-6736(93)91199-v. [DOI] [PubMed] [Google Scholar]
  6. Riley R. J., Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 1992 Apr 15;43(8):1657–1669. doi: 10.1016/0006-2952(92)90694-e. [DOI] [PubMed] [Google Scholar]
  7. Ross D., Beall H., Traver R. D., Siegel D., Phillips R. M., Gibson N. W. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res. 1994;6(10-11):493–500. [PubMed] [Google Scholar]
  8. Ross D., Siegel D., Beall H., Prakash A. S., Mulcahy R. T., Gibson N. W. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev. 1993 Jun;12(2):83–101. doi: 10.1007/BF00689803. [DOI] [PubMed] [Google Scholar]
  9. Ross D., Traver R. D., Siegel D., Kuehl B. L., Misra V., Rauth A. M. A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer. 1996 Sep;74(6):995–996. doi: 10.1038/bjc.1996.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rosvold E. A., McGlynn K. A., Lustbader E. D., Buetow K. H. Re: Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst. 1995 Dec 6;87(23):1802–1803. doi: 10.1093/jnci/87.23.1802. [DOI] [PubMed] [Google Scholar]
  11. Siegel D., Gibson N. W., Preusch P. C., Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990 Dec 1;50(23):7483–7489. [PubMed] [Google Scholar]
  12. Traver R. D., Horikoshi T., Danenberg K. D., Stadlbauer T. H., Danenberg P. V., Ross D., Gibson N. W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992 Feb 15;52(4):797–802. [PubMed] [Google Scholar]
  13. Walton M. I., Smith P. J., Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun. 1991 Jul;3(7):199–206. doi: 10.3727/095535491820873164. [DOI] [PubMed] [Google Scholar]
  14. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res. 1994;6(10-11):461–475. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES